Elysium Health and Basis, the Company’s Premier Supplement

Elysium Health was founded by Leonard Guarente, the director of the Paul F. Glenn Center for Biology of Aging Research at the Massachusetts Institute of Technology, and two businessmen, Eric Marcotulli and Dan Alminana.

Elysium Health is becoming a popular consumer health company, largely due to the firm’s supplement Basis. The supplement first hit the market in 2015.

The Science Behind Basis

Basis works by increasing levels of NAD+ in our cells. NAD+ is a coenzyme that is essential for DNA maintenance , energy creation, circadian rhythms, and hundreds of other vital functions. As we age, our levels of NAD+ decrease and those functions break down. Basis works to increase levels of NAD+ in our cells and support our cellular well-being as a result.

The Contents of Basis

Basis can be purchased in jars of 60 capsules, enough supplements to be taken twice daily for thirty days. The supplement has two main components, 250 milligrams of nicotinamide riboside and 50 milligrams of pterostilbene in each capsule.

Dr. Guarente had worked with the ingredients found in Basis since 1982, when he first became the Director of the Glenn Laboratory for the Science of Aging.

The Basis Clinical Trial

Basis is one of the few supplements available for purchase to have undergone a clinical trial to affirm the claims its manufacturer makes.

One hundred twenty adults—between 60 and 80 years of age—were selected to take part in the trial over the course of two months. Participants were split into three groups. Group one took a daily placebo; group two took two capsules of Basis per day (the daily recommended dose); and group three took four capsules of Basis (double the recommended daily dose of Basis).

The results, published in the academic journal npj: Aging and Mechanisms of Disease, demonstrated that after four weeks, the group taking two capsules of Basis daily experienced an average increase of 40 percent in NAD+ levels. The group taking four capsules of Basis daily experienced an average increase of 90 percent in NAD+ levels. (The increases were sustained throughout the duration of the trial.) Participants taking the placebo did not experience an increase in their NAD+ levels.

Elysium Health continues to research other products for future market release aimed at helping people live longer, healthier lives.